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Limited clinical benefit has been demonstrated for chimeric antigen receptor (CAR) therapy of solid tumors, but coengineering
strategies to generate so-called fourth-generation (4G) CAR-T cells are advancing toward overcoming barriers in the tumor
microenvironment (TME) for improved responses. In large part due to technical challenges, there are relatively few
preclinical CAR therapy studies in immunocompetent, syngeneic tumor-bearing mice. Here, we describe optimized methods
for the efficient retroviral transduction and expansion of murine T lymphocytes of a predominantly central memory T cell
(TCM cell) phenotype. We present a bicistronic retroviral vector encoding both a tumor vasculature–targeted CAR and murine
interleukin-15 (mIL-15), conferring enhanced effector functions, engraftment, tumor control, and TME reprogramming,
including NK cell activation and reduced presence of M2 macrophages. The 4G-CAR-T cells coexpressing mIL-15 were further
characterized by up-regulation of the antiapoptotic marker Bcl-2 and lower cell-surface expression of the inhibitory receptor
PD-1. Overall, this work introduces robust tools for the development and evaluation of 4G-CAR-T cells in immunocompetent
mice, an important step toward the acceleration of effective therapies reaching the clinic.
Introduction
The adoptive cell transfer (ACT) of ex vivo–expanded T lym-
phocytes has yielded robust and durable clinical responses
against several cancer-types, such as tumor-infiltrating lym-
phocyte therapy of advanced melanoma (Mardiana et al., 2019).
Another approach to ACT involves the redirection of peripheral
blood T cells to tumor antigens by engineering them to express a
chimeric antigen receptor (CAR) that triggers cellular activation
upon tumor antigen binding. CAR-T cell therapy against he-
matologic malignancies, by targeting the B cell lineage antigens
CD19 or the B cell maturation antigen, has proven efficacious in
the clinic, and there is optimism that similar success will be
achieved for some solid tumors (Geyer and Brentjens, 2016;
Irving et al., 2017).
A range of physical (Lanitis et al., 2015) and immunometabolic
barriers that can prevent T cell homing, transendothelial migra-
tion across tumor blood vessels, engraftment/persistence, and
effector function limit the potency of CAR-T cell therapy
against solid tumors (Brown et al., 2016; Louis et al., 2011).
Moreover, chronic antigen exposure and a lack of sufficient
costimulation in the tumor microenvironment (TME) can cause
CAR-T cell exhaustion (Irving et al., 2017). Coengineering of
CAR-T cells may help to overcome some of these obstacles
(Lanitis et al., 2020). Genetic modifications, for example, can be
made to enable better homing and tumor penetration or render
CAR-T cells resistant to suppressive mechanisms in the TME
(Stromnes et al., 2010). In addition, CAR-T cells can be armed
with secretory molecules or additional receptors to support
CAR-T cell activity and/or harness endogenous immunity
(Adachi et al., 2018; Pegram et al., 2012).
Preclinical evaluation of CAR-T cells has, for the most part,
been performed with xenograft tumor models in immunodefi-
cient mice (Lee et al., 2011; Mardiros et al., 2013; Lanitis et al.,
2012). Although this approach can be used to evaluate human
CAR-T cell persistence, homing, tumor control, and survival
following ACT, critical parameters, including potential toxicity
against normal tissues (Tran et al., 2013), and the impact of
endogenous immunity on both tumor control and escape are not
addressed in such models (Spear et al., 2012; Avanzi et al., 2018).
As varying obstacles must be overcome to enhance CAR-T cell
responses against different solid tumor types, comprehensive
studies in immunocompetent syngeneic tumor models would
enable more accurate screening of T cell engineering strategies
and provide important insights into improving coengineering
and combinatorial treatment approaches (Lanitis et al., 2020).
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A key limitation of CAR evaluation in syngeneic models
stems from inadequate methodologies for efficient murine T cell
transduction and expansion. Indeed, unless T cells derived from
multiple donor spleens are transduced or the engineered T cells
are restimulated for further expansion, which among other
drawbacks are costly and can promote exhaustion and apoptosis
(Bucks et al., 2009), respectively, current protocols yield in-
sufficient numbers of CAR-T cells for ACT studies (Lee et al.,
2009). The efficiency of cell-surface expression of second-
generation (2G) CARs, comprising the endodomain (ED) of
CD3ζ and one costimulatory ED (e.g., CD28 or 4-1BB), generally
reaches 40–60% (Kochenderfer et al., 2010; Davila et al., 2013;
Wang et al., 2014; Fu et al., 2013). Although retroviral trans-
duction rates as high as 70–80% for murine T cells have been
reported, this was assessed at 2 to 3 d after transduction (Tran
et al., 2013; Kuhn et al., 2019; Kusabuka et al., 2016) and thus
may include false positives due to transient expression from
nonintegrated vector DNA (i.e., pseudo-transduction; Case et al.,
1999, Costello et al., 2000). Moreover, short-term transduction
efficiency is often based on reporter genes like GFP, which may
overestimate CAR expression levels (Kusabuka et al., 2016; Kuhn
et al., 2019; Davila et al., 2013). Finally, while stable retroviral
packaging and producer cell lines may enable transduction ef-
ficiencies for 2G and third-generation (3G; i.e., a CAR having two
ormore costimulatory EDs) CARs of >60% (Fu et al., 2013), this is
a laborious approach if multiple CAR designs are to be compared
(Chinnasamy et al., 2010).
Here, we report the development of an efficient and highly
reproducible protocol for primary murine T cell retroviral
transduction and expansion, yielding functional murine 2G-
CAR-T cells, as well as fourth-generation (4G)-CAR-T cells
coengineered to express murine IL-15 (mIL-15) for enhanced
in vitro and in vivo function and TME reprogramming. Overall,
our work provides important tools for enabling the systematic
evaluation of 4G-CAR-T cells in immunocompetent, syngeneic
tumor-bearing mice, which we believe is critical for effective
therapies reaching the clinic.
Results
Optimal retrovirus preparation, T cell activation, and
transduction enables efficient cell-surface CAR expression
We sought to optimize murine T cell activation, transduction,
and expansion methods for preclinical CAR therapy evaluation
in immunocompetent, syngeneic tumor-bearing mice. The final
protocol we developed is summarized in Fig. 1 and is described
in detail in Materials and methods. We used a 2G-CAR targeting
vascular endothelial cell growth factor receptor 2 (VEGFR-2),
comprising the well-characterized single-chain variable frag-
ment (scFv) DC101 (Chinnasamy et al., 2010), a CD8α hinge and
transmembrane domain, and the murine EDs of CD28 and CD3ζ.
The anti-VEGFR-2 CAR retroviral vector is abbreviated as DC101-28z
(Fig. 2 A).
Because retroviruses infect proliferating cells (Kusabuka
et al., 2016; Chinnasamy et al., 2010; Hu et al., 2017), we first
compared three commonly used methods for inducing T cell
activation: (i) magnetic beads coated with anti-(α) CD3 antibody
(Ab) and αCD28 Ab (αCD3/CD28 beads) plus recombinant hu-
man IL-2 (hIL-2), (ii) plate-immobilized αCD3 Ab along with
soluble αCD28 Ab (αCD3-plate/CD28) plus hIL-2, and (iii) Con-
canavalin A plus hIL-2 and hIL-7. Stimulation with αCD3/CD28
beads consistently resulted in the highest frequency of CD44+
CD62L− (recently activated, memory), CD25+ or CD69+ (acti-
vated), and Ki67+ (proliferating) CD3+ T cells (Fig. 2 B and Fig.
S1 A).
We next found that concentration of viral particles through
ultracentrifugation yielded higher viral titers (>3 × 107 trans-
ducing units/ml; Fig. 2 C) and enabled significantly higher
transduction of primary activated primary murine T cells as
compared with unconcentrated retrovirus (Fig. 2 D), reaching a
plateau at a multiplicity of infection (MOI) of 5 (∼80% CAR
expression; Fig. 2 E). A single transduction at 24 h after activa-
tion versus transduction at both 24 and 48 h did not affect the
efficiency in terms of either percentage of cells transduced or
CAR expression level per cell (i.e., mean fluorescence intensity
[MFI]; Fig. 2, E and F). We observed, however, that the trans-
duction efficiency at 48 h after activation was inferior to that
obtained at 24 h after activation (Fig. 2, E and F). A schema of the
T cell activation and transduction approaches compared are
depicted in Fig. 2 G.
Finally, we observed highest CAR transduction efficiency in
CD3+ lymphocytes activated with αCD3/CD28 beads in the
presence of hIL-2 as compared with the other aforementioned
activation methods (Fig. 2, H and I). Similar results were ob-
served for CD8+ T cells, while for CD4+ T cells, the percentage
CAR expression was the same for both αCD3/CD28-bead and
αCD3-plate/CD28 activation (Fig. S1 B). Thus, αCD3/CD28-bead
activation was used for all further experiments. Notably, we also
investigated concentrated lentiviral transduction of αCD3/CD28-
bead–activated murine T cells using the same anti-VEGFR-
2 CAR, and consistent with another study (Kerkar et al., 2011),
we obtained very low transduction efficiency (∼10%, data not
shown).
Culture in the presence of hIL-7 and IL-15 ameliorates murine
CAR-T cell expansion, survival, and cytokine production, and
promotes a central memory phenotype
While long-term T cell culture in IL-2 drives terminal differ-
entiation, the common γ-chain cytokines IL-7 and IL-15 have
been reported to promote a central memory T cell (TCM cell)
phenotype enabling superior persistence and in vivo tumor
control upon ACT (Klebanoff et al., 2005). Thus, we next com-
pared the expansion and functional properties of transduced
murine CAR-T cells cultured in hIL-2 alone versus hIL-2 for the
first 3 days, followed by hIL-7/IL-15 for the remainder of the
culture period (Fig. 3 A). Both hIL-7 and hIL-15 have been pre-
viously demonstrated to act on murine T cells to promote ho-
meostatic proliferation and survival (Eisenman et al., 2002;
Nanjappa et al., 2008).
As for hIL-2–expanded CAR-T cells (Fig. 2 G), we observed
that a single transduction of T cells at 24 h and subsequent ex-
pansion in hIL-7/IL-15 was sufficient to achieve a robust and
stable transduction efficiency at aMOI as low as 5 (Fig. 3 B). Both
culture conditions (hIL-2 alone versus hIL-2 followed by hIL-7/
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IL-15) enabled high CAR expression on day 7 (Fig. 3 C). On day 9,
however, we observed a 26-fold expansion of CAR-T cells ex-
posed to hIL-7/IL-15 as compared with a 9-fold expansion in the
presence of hIL-2 alone at a standard concentration of 50 IU/ml
(Fig. 3 D). Moreover, CAR-T cells cultured with hIL-7/IL-15
continued to expand for at least 14 d, while T cells cultured in
hIL-2 alone reached a plateau after 1 wk (Fig. 3 D) and exhibited
significantly higher levels of cell death starting early in the
culture (Fig. 3 E). We also observed a significantly higher
frequency of CD8+ T cells in the hIL-7/IL-15 culture (Fig. 3 F).
Finally, transduced T cells expanded with hIL-7/IL-15 had a
significantly higher proportion of TCM cells based on cell-surface
Figure 1. Overview of retrovirus production and transduction of activated primary murine T cells. (A) For retrovirus production, plated Phoenix Eco
cells are transfected with Turbofect and plasmid mix. After 24 h the medium is refreshed, and at 48 and 72 h, the supernatants are collected, and the virus is
concentrated by ultracentrifugation and directly used or frozen. (B) For the transduction of primary murine T cells, retrovirus is applied to plates precoated
with retronectin and then spun. Activated T cells are then added to the plate, which is subsequently spun. At 48 h after transduction, the T cells are split and
hIL-7/IL-15 added to the culture medium. At day 7 after transduction, CAR cell-surface expression is determined by flow cytometry, and the engineered T cells
are evaluated in vitro and in vivo. Further details are provided in Materials and methods.
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Figure 2. Concentration of retrovirus and optimal T cell activation increases transduction efficiency. (A) Diagram of the 2G VEGFR-2–targeted CAR
construct (DC101-28z) comprising an Igκ chain leader sequence, the hinge and transmembrane (TM) region of CD8α, the costimulatory ED of CD28, and the ED
of CD3ζ (DC101, αVEGFR-2 scFv; L, linker; VH, variable heavy chain; VL, variable light chain). (B) Comparison of activation state of differently stimulated T cells.
Numbers represent mean percentage of expression ± SEM of T cells from n = 6 mice pooled from two independent experiments. (C) Virus titer with and
without concentration by ultracentrifugation as determined with transduced T cells on day 7 after transduction. Numbers represent mean MOI ± SEM cal-
culated in transduced T cells from n = 3 mice. TU, transducing units. (D) CAR expression on T cells transduced with serially diluted retrovirus as evaluated by
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expression of the hyaluronic acid receptor CD44 and the
L-selectin CD62L from day 5 after cytokine addition (Fig. 3, G
and H).
We sought to evaluate the in vitro reactivity of hIL-2 only
versus hIL-7/IL-15 expanded CAR-T cells against target antigen.
On day 7 after transduction, we co-cultured CAR-T cells with
bEnd3 murine endothelial cells expressing VEGFR-2, as well as
with control VEGFR-2− H5V murine endothelial cells (Fig. 3 I).
hIL-7/IL-15 expanded CAR-T cells secreted significantly higher
levels of IFN-γ, granzyme B, and IL-2 (Fig. 3 J) after bEnd3 target
cell recognition in vitro. Because CAR-T cell expansion with hIL-
7/IL-15 results in a higher frequency of CD8+ T cells as compared
with hIL-2 only, we next sorted CD8+ T cells on day 7 after
transduction and performed a co-culture with bEnd3 and H5V
cells. Higher levels of granzyme B, IL-2, and IFN-γwere secreted
by hIL-7/IL-15–expanded CD8+ CAR-T cells than hIL-2–expanded
ones (Fig. S2). Moreover, hIL-7/IL-15–expanded CAR-T cells
exhibited significantly higher persistence (Fig. 3 K), division
rates (Fig. 3 L), and numbers of proliferating CD8+ T cells after
4 d of co-culture (Fig. 3 M). Thus, as compared with hIL-2 alone,
CAR-T cell expansion with hIL-7/IL-15 promotes higher viability
and favors a TCM cell phenotype, more robust expansion, and
superior secretion of cytokines and long-term proliferative ca-
pacity upon challenge with target cells.
High rate of CAR-T cell transduction is achieved with a 4G-CAR
retroviral vector coexpressing mIL-15
The high transduction efficiency achieved with our optimized
method encouraged us to evaluate the coexpression of trans-
genes and test the impact of additional cargo on CAR-T cell
performance. Given the enhanced functional properties of CAR-
T cells exposed to hIL-7/IL-15 at 48 h after transduction as op-
posed to hIL-2 alone, we focused on coengineering T cells to
constitutively produce mIL-15. Notably, hIL-15 has been previ-
ously demonstrated to significantly improve the antitumor ac-
tivity of human CAR-T cells targeting glioblastoma (Krenciute
et al., 2017).
A bicistronic retroviral vector encodingmIL-15 and the DC101
CAR, both driven by the 59 LTR of the retrovirus (de Felipe et al.,
1999) and separated by a self-cleaving 2A peptide sequence (T2A;
Liu et al., 2017), was built to express this 4G-CAR construct
(Fig. 4 A). With a single round of transduction at a MOI as low as
5, we achieved a similarly high expression of the 4G- as the 2G-
CAR (Fig. 4, B and C), as well as high intracellular expression of
mIL-15 (Fig. 4 D). Significant mIL-15 was also detected by ELISA
upon lysis of 4G-CAR-T cells (Fig. 4 E), but very low levels of
mIL-15 were found in the culture supernatant (data not shown),
presumably due to sequestration of the cytokine by cell-surface
IL-15 receptor-α (IL-15-Rα), as has been previously observed for
human T cells engineered to secrete hIL-15 (Markley and
Sadelain, 2010). Our hypothesis was supported by the fact that
we detected high levels of soluble mIL-15 in the supernatants of
transfected human Phoenix Eco cells (i.e., the retrovirus pro-
ducer cell line; Fig. 4 F). Moreover, 4G-CAR–transduced C1498
leukemia cells (which do not express IL-15-Rα; Fig. S3 A) se-
creted high levels of mIL-15 (Fig. 4, G and H). Finally, we acti-
vated both 2G- and 4G-CAR-T cells with cognate antigen and
found significant secretion of mIL-15 by the 4G-CAR-T cells
(Fig. 4 I), as has similarly been reported in the context of en-
gineered human T cells (Krenciute et al., 2017).
Coexpression of mIL-15 confers enhanced CAR-T cell fitness
We next sought to investigate the impact of mIL-15 coexpression
on CAR-T cell signaling and phenotype. In the absence of ex-
ogenous cytokine in the culture supernatant, we observed ele-
vated pSTAT5 in the 4G- versus 2G-CAR-T cells both in terms
of frequency and level per cell (Fig. 4, J and K). We further
evaluated IL-15-Rα expression and detected lower levels on 4G-
CAR-T cells (Fig. 4, L and M), presumably due to receptor in-
ternalization (Dubois et al., 2002) and/or mIL-15 occupancy
blocking the Ab binding site. Subsequently, we assessed ex-
pression of the antiapoptotic protein Bcl-2, previously reported
to enhance 2G- versus first-generation (1G)–CAR-T cell persis-
tence (Song et al., 2012), and found higher expression levels on
days 2 and 5 after transduction for 4G- as compared with 2G-
CAR-T cells in the absence of exogenous cytokines (Fig. S3, B and
C). In addition, we observed significantly higher frequencies of
Ki67+ Bcl-2+ 4G-CAR-T cells on days 2 and 5 after transduction
(Fig. 5, A and B). Thus, mIL-15 coexpression appears to augment
both CAR-T cell survival and proliferation.
We further assessed the phenotype of CAR-T cells in the
absence of exogenous cytokines in the culture medium and
found that on day 2 following transduction, 2G- and 4G-CAR-
T cells displayed no differences in the proportion of naive
(CD62Lhigh CD44low), central memory (CM; CD62Lhigh CD44high)
and effector memory (EM; CD62Llow CD44high) T cell phenotype
populations. However, by day 5 after transduction, 4G-CAR-
T cells had a higher proportion of naive and CM cells and fewer
EM cells, as compared with 2G-CAR-T cells (Fig. 5, C and D).
Notably, there were significantly lower levels of the inhibitory
receptor programmed cell death 1 (PD-1; both percentage and
MFI) on 4G- compared with 2G-CAR-T cells (Fig. 5, E and F).
Consistent with the above findings, we observed that in the
absence of exogenous cytokine the 4G-CAR-T cells exhibited
increased expansion during the first 2 d after transduction
as compared with the 2G-CAR-T cells (Fig. 5 G). Both 2G- and
flow cytometric analysis. Numbers represent mean percentage of CAR expression ± SEM of T cells from n = 3 mice. Representative histograms of transduced
T cells with the indicated dilutions of retroviral supernatants shown. (E) Murine T lymphocytes were transduced once (1×) or twice (2×) after activation (24
and/or 48 h) at increasing MOI. Numbers represent mean percentage of MFI CAR ± SEM of T cells from n = 3 mice. (F) Representative histograms showing CAR
frequency and expression level at day 7 after transduction. The experiments in C–F were repeated three times. (G) Schematic diagram of different murine T cell
activation and transduction methods tested. (H) Evaluation of CAR frequency following different activation methods. Numbers represent mean percentage of
CAR ± SEM of T cells from n = 5 mice pooled from two independent experiments. (I) Representative histograms of CAR expression for differently activated
T cells at day 7 after transduction. Statistical analyses were performed using a one-way ANOVA with Tukey post hoc correction test (B and H) and a two-tailed
unpaired Student’s t test (C): *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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Figure 3. CAR-T cells cultured with hIL-2 followed by hIL-7/IL-15 exhibit greater expansion, viability, and central memory phenotype than CAR-T
cells culturedwith hIL-2 only. (A)Overview of primary murine T cell activation, transduction, and expansion. On day 2 after transduction, the culture medium
was supplemented with hIL-2 or hIL-7/IL-15. (B) CAR expression on splenic murine T cells transduced either at 24 h only, or at 24 and 48 h after activation,
at increasing MOI. Values represent mean percentage and MFI CAR expression ± SEM of T cells from n = 3 mice. The experiment was repeated twice.
(C) Representative flow cytometry data of CAR expression on day 7 after the first transduction in transduced T cells cultured in hIL-2 only, or hIL-2 plus hIL-7/IL-15
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4G-CAR-T cells began to contract at a similar rate from day
2 after transduction, but there were significantly more 4G- than
2G-CAR-T cells on days 5 and 7 (Fig. 5 G). Finally, we observed
higher viability of 4G-CAR-T cells over time (Fig. 5 H). Thus,
with our optimized protocol, we achieved a high rate of T cell
transduction with retrovirus coexpressing a CAR and mIL-15,
and in the absence of exogenous cytokines, these 4G-CAR-
T cells exhibit a less differentiated and inhibitory phenotype as
well as enhanced expansion and viability in vitro.
Coexpression of mIL-15 by CAR-T cells boosts expansion and
enhances in vitro cytokine production and proliferation
We next sought to evaluate the expansion of 4G- versus 2G-CAR-
T cells in the presence of exogenous hIL-7/IL-15. We observed
continuous expansion of 4G- and 2G-CAR-T cells for 2 wk but at
a significantly higher rate for the 4G-CAR-T cells (Fig. 6 A).
Viability was similarly high for both over a 10-d period (Fig. 6 B).
Notably, 4G-CAR-T cells cultured in hIL-2 demonstrated en-
hanced expansion at days 5 and 9 as compared with similarly
cultured 2G-CAR-T cells (Fig. 6 C). We subsequently sought to
determine if increasing hIL-15 levels in the medium could aug-
ment 2G-CAR-T cell expansion. We demonstrated that 2G-CAR-
T cells cultured in the presence of increasing concentrations of
hIL-15 (while maintaining hIL-7 at 10 ng/ml) achieved signifi-
cant increases in fold expansion, reaching or surpassing that of
4G-CAR-T cells (cultured in standard 10 ng/ml hIL-15) at day 9
after transduction in the presence of 50 ng/ml or 100 ng/ml hIL-
15, respectively (Fig. 6 D and Fig. S3 D). Notably, increasing the
concentration of hIL-15 in the culture medium from 10 to 50 or
100 ng/ml significantly increased the expansion of 4G-CAR-
T cells (Fig. 6 E), and the fold expansion of 4G-CAR-T cells was
nearly double compared to that of 2G-CAR-T cells (cultured in
equivalent increased hIL-15 concentrations) on day 9 after trans-
duction (Fig. 6 E and Fig. S3 D).
We next tested the effector capacity of 4G- as compared with
2G-CAR-T cells against target cells. Significantly higher levels of
IL-2 were produced by 4G- than 2G-CAR-T cells upon co-culture
with VEGFR-2+ bEnd3 cells at 1 wk after transduction, while
neither reacted against VEGFR-2− H5V cells (Fig. 6 F). We fur-
ther observed mIL-15 secretion by 4G-CAR-T cells only upon co-
culture with bEnd3 cells and not H5V cells (Fig. 6 G). In addition,
there was significantly higher expansion of 4G- than 2G-CAR-
T cells at day 4 after co-culture with bEnd3 cells, and neither
expanded upon co-culture with H5V cells (Fig. 6, H and I). The
4G-CAR-T cells also exhibited significantly higher proliferation
(Fig. 6 J) and numbers of dividing CD8+ T cells compared with
2G-CAR- or control T cells at day 4 of the co-culture (Fig. 6, K and
L). The ability of 4G- and 2G-CAR-T cells to induce apoptosis of
target cells was equivalent (Fig. 6 M, and N), in accordance with
previous evaluation of hIL-15-CAR-T cells (Krenciute et al.,
2017).
CAR-T cells coexpressing mIL-15 exhibit increased in vivo
persistence and tumor control
We further tested the 4G- and 2G-CAR-T cells in vivo against
subcutaneous B16 melanoma tumors. Briefly, on day 8 after
tumor cell injection, with tumors approaching 20–40 mm3 in
volume, CD45.2+ C57BL/6 mice were lymphodepleted by suble-
thal total body irradiation and subsequently received two in-
travenous T cell injections (8–9 × 106 CD45.1+ cells at each
injection; Fig. 7 A). In mice treated with control T cells, the tu-
mors grew rapidly, while modest tumor control was observed in
mice that received 2G-CAR-T cells, similar to previous reports
for this tumor vasculature targeting CAR (Chinnasamy et al.,
2010, 2012). Mice treated with 4G-CAR-T cells, however, had
significantly attenuated tumor growth (Fig. 7 B).
Ex vivo analysis of transferred CD45.1+ T cells in the blood,
spleen, and tumor on day 11 after ACT revealed significantly
higher engraftment of 4G- than 2G-CAR-T cells and control
T cells (Fig. 7, C–E). In addition, CAR expression levels were
higher for 4G- than 2G-CAR-T cells in blood, spleen, and tumor
(Fig. 7, C, D, and F). Notably, we observed sustained presence of
the mIL-15 transgene in the spleens and tumors of mice treated
with 4G-CAR-T cells (Fig. 7, D and F). Finally, in agreement with
our in vitro data, 4G-CAR-T cells expressed significantly higher
levels of the antiapoptotic protein Bcl-2 in vivo (Fig. 7 G; flow
cytometry gating strategy shown in Fig. S4). Thus, mIL-15 co-
expression by CAR-T cells enhances not only expansion and
in vitro effector functions but also in vivo persistence and tumor
control.
IL-15–CAR-T cells are characterized by lower PD-1 expression
than 2G-CAR-T cells in vivo, and they reprogram the TME
Finally, we sought to comprehensively evaluate the effect of
mIL-15 coexpression on CAR-T cells in vivo and to determine if
endogenous immune cells are also impacted. Following the same
ACT strategy as demonstrated above (Fig. 8 A), we observed that
4G-CAR-T cells in the spleen (Fig. 8, B and C) and tumor-draining
from day 2 after first transduction. Thy1.1-T cells were used as a negative control. (D and E) CAR-T cell expansion (D) and viability (E) upon culture in hIL-2 versus
hIL-2 followed by hIL-7/IL-15. The graphs show themean percentage of expansion (D) or viability (E) ± SEM of T cells from n = 4mice pooled from two independent
experiments. (F) Percentage of CD8+ T cells upon expansion in hIL-2 versus hIL-7/IL-15. Shown are the mean percentage of CD8+ T cells ± SEM from n = 4
mice. (G) Percentage of TCM cells (CD44+ CD62L+) upon expansion in hIL-2 versus hIL-7/IL-15. Numbers represent the mean percentage of TCM cells ± SEM
from n = 4 mice pooled from two independent experiments. (H) Representative flow cytometric analysis for G on day 7 after cytokine addition. Experiments
in D–H were repeated four times. (I) Flow cytometric analysis of endothelial cells stained with αVEGFR-2 Ab. The MFI values are indicated. (J) Secretion
levels of IFN-γ, granzyme B, and IL-2 by CAR-T cells expanded in hIL-2 versus hIL-7/IL-15 upon co-culture with bEnd3 or H5V cells. Graph bars present the
mean cytokine concentration (pg/ml) ± SEM from triplicate wells with T cells pooled from n = 4 mice. (K–M) Persistence (K) and division (L and M) of CTV-
stained CAR-T cells expanded in hIL-2 or hIL-7/IL-15 upon co-culture with target cells. Graphs present the mean values ± SEM of T cells from n = 3 mice.
Representative flow cytometric analysis for the CTV proliferation assay is shown in M. Experiments in I–M were repeated three times. Statistical analyses
were performed using a two-tailed unpaired Student’s t test (D–G) and a one-way ANOVAwith Tukey post hoc correction test (J–M): *, P < 0.05; **, P < 0.01;
***, P < 0.001; ****, P < 0.0001.
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Figure 4. Murine T cells efficiently transduced to coexpress anti-VEGFR-2 CAR and functionally active mIL-15. (A) Comparison of the 2G-CAR construct
(DC101-28z) and a bicistronic vector encoding both mIL-15 and the anti-VEGFR-2 CAR (4G-CAR construct). (B) Murine T cells were transduced once (1×) or
twice (2×) with 4G-CAR retrovirus at 24 h or 24 and 48 h after activation at increasing MOI. Numbers represent mean percentage and MFI of CAR ± SEM for
T cells from n = 3 mice. The experiment was repeated twice. (C) Representative flow cytometry data of 2G- and 4G-CAR expression by murine T cells on day 7
after transduction. (D) Representative flow cytometry plots showing intracellular mIL-15 production by 4G-CAR-T cells as compared with 2G-CAR-T cells and
Thy1.1-T cells. The experiment was performed using T cells pooled from n = 4 mice and was repeated three times. (E) mIL-15 protein expression by 4G-CAR-
T cells determined by ELISA of the supernatant of lysed T cells. Results are presented as the mean concentration (pg/ml) ± SEM from triplicate wells with
T cells pooled from n = 4 mice. The experiment was repeated twice. (F) Evaluation of mIL-15 levels in the supernatant of Phoenix cells 72 h after transfection.
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lymph nodes (Fig. S5, A and B) exhibited a higher frequency of
Ki67 (cellular marker for proliferation) than 2G-CAR-T cells. In
the tumor, despite that Ki67 expression levels were similar for
both 4G- and 2G-CAR-T cells (Fig. 8, D and E), the 4G-CAR-T cells
displayed significantly lower levels of PD-1 (Fig. 8, F and G).
Analysis of endogenous immune infiltrate revealed significantly
higher coexpression of CD69 and Ki67 by natural killer (NK) cells
in 4G- as compared with 2G-CAR-T cell–treated tumors (Fig. 8, H
and I). In addition, in 4G-CAR-T cell–treated mice there were
lower levels of tumor-residing M2 (F4/80+ CD206+) macro-
phages, which are often associated with immunosuppression in
the TME (Fig. 8 J, K). Both the activation of NK cells and lower
levels of M2 macrophages may contribute to tumor control in the
context of 4G-CAR-T cell transfer. Tumor-residing B cells (CD19+
MHC II+) were not detected (Fig. S5, C and D), and there were
no differences in splenic B cell frequency in any of the treated
mice (Fig. S5, E and F). Finally, similar frequencies of tumor-
residing dendritic cells (DCs; CD11b− CD11c+) were observed
among the control and CAR-T cell–treated mice (Fig. S5, G and
H). The flow cytometry gating strategy for the ex vivo char-
acterization of the different immune cell populations is shown
in Fig. S4. Thus, 4G-CAR-T cells coexpressing mIL-15, in ad-
dition to conferring enhanced tumor control as compared
with 2G-CAR-T cells, also reprogram the TME in favor of
protective endogenous immunity.
Discussion
CAR-T cell therapy has yielded unprecedented clinical responses
against some hematological malignancies, but not against epithelial-
derived solid tumors (Irving et al., 2017). Rational combinatorial
treatments and innovative CAR-T cell coengineering strategies
(Lanitis et al., 2020) offer solutions for overcoming obstacles in
the solid TME, but these are best evaluated in immunocom-
petent mice to enable the interplay of the endogenous immune
system. In this study, we have presented optimized conditions
for murine T cell activation, retroviral transduction, and ex-
pansion that allowed us to achieve consistently high and stable
transgene expression levels, as well as robust expansion of both
2G- and 4G-CAR-T cells having a predominantly TCM cell phe-
notype, which is favored for ACT (Melchionda et al., 2005;
Gattinoni et al., 2005; Zhou et al., 2005). We have also eluci-
dated the beneficial impact of mIL-15 coexpression by murine
CAR-T cells both in vitro and in vivo.
Retroviral vectors, most commonly derived from the murine
stem cell virus (MSCV), a derivative of the Moloney murine
leukemia virus, have proven to be the most effective approach
for stably introducing genes into murine T cells (Kerkar et al.,
2011). Lentivirus, however, has demonstrated poor gene transfer
in murine T cells, likely due to impaired completion of reverse
transcription and of nuclear import of the viral preintegration
complex (Baumann et al., 2004; Tsurutani et al., 2007). Most
examples of efficient murine T cell retroviral transduction are
for small and easily expressed reporter genes like GFP (Kurachi
et al., 2017; Zhang et al., 2003) or 1G-CARs comprising the CD3ζ
endodomain only (Lee et al., 2009). Retrovirus-mediated ex-
pression of 2G-CARs has proven less robust both in terms of
percentage transduction and expression level per T cell (Kochenderfer
et al., 2010; Davila et al., 2013; Fu et al., 2013). Moreover, the long-
term stability of CAR expression by murine T cells has not
previously been thoroughly evaluated (Kusabuka et al., 2016;
Kochenderfer et al., 2010).
Despite that it is common procedure to concentrate lentivirus
via ultracentrifugation, this is usually not performed for CAR-
encoding retroviruses. In this study, we demonstrated that ret-
rovirus can be efficiently concentrated, leading to significantly
improved CAR transduction efficiencies. We further observed a
correlation between CD8+ T cell activation levels (the highest level
was achieved by αCD3/CD28 bead stimulation) and transduction
efficiency. Previous studies have presented CAR expression early
after transduction (2–3 d; Tran et al., 2013; Kusabuka et al., 2016;
Kochenderfer et al., 2010) and thus cannot distinguish from
pseudo-transduction (Case et al., 1999; Costello et al., 2000). In
addition, some studies have applied antibiotic selection for en-
richment of CAR-T cells (Kusabuka et al., 2016) or have measured
GFP (or other markers) that can overestimate transduction effi-
ciency. Here, we have demonstrated robust, long-term CAR ex-
pression in murine T cells by staining with recombinant target
antigen and in the absence of any selection/enrichment method.
In this study, we have also shown the utility of the common
γ-chain cytokines hIL-7/IL-15 for enhanced CAR-T cell expan-
sion and survival, as well as for promoting a TCM cell phenotype
and ameliorating effector function. Others have reported supe-
rior tumor control by IL-7/IL-15 than IL-2–expanded T cells (Cha
et al., 2010; Gattinoni et al., 2005; Mueller et al., 2008). It has
also been previously demonstrated that exposure of murine
T cells to IL-2 can potentiate apoptosis by suppressing the in-
hibitor of Fas signaling, FLIP (FLICE-inhibitory protein), and
enhancing the expression of the proapoptotic molecule Fas lig-
and (Lenardo, 1991; Refaeli et al., 1998). In contrast, IL-7 and IL-
15 inhibit activation-induced cell death, support the prolifera-
tion and survival of T cells (Waldmann, 2015; Jiang et al., 2004;
Results are presented as the mean concentration (pg/ml) ± SEM of triplicate wells. The experiment was repeated four times. (G) Flow cytometry histograms
showing CAR expression on C1498 murine leukemia cells transduced to express 2G- or 4G-CAR or Thy1.1. (H) mIL-15 detected in the supernatant of 4G-CAR
engineered C1498 leukemia cells. Results show the mean concentration (pg/ml) ± SEM of triplicate wells. (I)Measurement of mIL-15 secretion by 2G- and 4G-
CAR-T cells at 24 h after stimulation with recombinant mVEGFR-2 or BSA. Numbers represent mean concentration (pg/ml) ± SEM of triplicate wells with T cells
pooled from n = 5 mice. (J) Phosphorylated (p) STAT5 expression by 2G- versus 4G-CAR-T cells on day 2 after transduction. Numbers represent mean per-
centage and MFI pSTAT5 ± SEM of T cells from n = 3 mice. (K) Representative flow cytometry histograms showing pSTAT5 frequency and levels in 2G- or 4G-
CAR-T cells. (L) IL-15-Rα expression by 2G- versus 4G-CAR-T cells on day 5 after transduction in the absence of exogenous cytokines. Numbers represent mean
frequency and MFI of IL-15-Rα ± SEM of T cells from n = 4 mice. (M) Representative flow cytometry histograms showing IL-15-Rα frequency and levels for 2G-
or 4G-CAR-T cells. Experiments in G–Mwere repeated three times. Statistical analyses in J and L were performed using a two-tailed unpaired Student’s t test:
***, P < 0.001; ****, P < 0.0001. FMO, fluorescence minus one; SSC-A, side scatter area.
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Cha et al., 2010), promote a TCM cell phenotype characterized by
longer telomeres, and elevate T cell persistence and antitumor
efficacy (Melchionda et al., 2005; Gattinoni et al., 2005; Zhou
et al., 2005; Klebanoff et al., 2004; Le et al., 2009). Similarly, it
has been shown that IL-7 and IL-15 enable enhanced human
CAR-T cell effector function upon antigen recognition (Xu et al.,
2014; Zhou et al., 2019) and that exogenous IL-15 can expand
anti-CD19 CAR-T cells in treated patients by up to 180-fold
(Ramanayake et al., 2015). Contradictory reports of lower mu-
rine T cell function in vitro following culture in IL-7/IL-15 versus
IL-2 alone are presumably due to the method of T cell stimula-
tion used, differences in the concentration of IL-2 used, and the
duration of expansion (Cha et al., 2010; Gattinoni et al., 2005;
Mueller et al., 2008).
Figure 5. 4G-CAR-T cells coexpressing mIL-15 exhibit enhanced in vitro fitness as compared with 2G-CAR-T cells. (A) Ki67 and Bcl-2 expression by 2G-
versus 4G-CAR-T cells on days 2 and 5 after transduction in the absence of exogenous cytokines. Results presented are mean percentage ± SEM of T cells from
n = 3 mice. (B) Representative flow cytometric analyses of 2G- and 4G-CAR-T cells stained with αKi67 and αBcl-2 Abs on days 2 and 5 after transduction.
(C) Percentages of naive (CD44low CD62Lhigh), CM (CD44high CD62Lhigh), and EM (CD44high CD62Llow) of 2G- versus 4G-CAR-T cells on days 2 and 5 after
transduction in the absence of exogenous cytokines. The analysis was performed using T cells derived from n = 3 mice. (D) Representative flow cytometry plots
showing CD44 and CD62L expression on 2G- and 4G-CAR-T cells. Experiments in A–D were repeated three times. (E) PD-1 expression by 2G- versus 4G-CAR-
T cells on day 5 after transduction in the absence of exogenous cytokines. Results present the mean percentage and MFI of PD-1 ± SEM of T cells from n = 3
mice. (F) Representative flow cytometry histograms showing PD-1 frequency andMFI for 2G- versus 4G-CAR-T cells. (G and H) Fold expansion (G) and viability
(H) of 2G- versus 4G-CAR-T cells in the absence of exogenous cytokines. Graphs present the mean fold expansion (G) or percentage of viability (H) ± SEM of
T cells from n = 3 mice. Experiments in E–H were repeated four times. Statistical analyses in A, C, E, G, and H were performed using a two-tailed unpaired
Student’s t test: *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 6. 4G-CAR-T cells coexpressing mIL-15 exhibit robust expansion during culture and enhanced IL-2 secretion and proliferation in response to
antigenic stimulation. (A and B) Expansion (A) and viability (B) of 2G- versus 4G-CAR-T cells in the presence of exogenous hIL-7/IL-15 from day 2 after
transduction. Results present the mean fold expansion (A) or percentage of viable cells (B) ± SEM of T cells from n = 4 mice pooled from two independent
experiments. Experiments in A and B were repeated four times. (C) Expansion of 2G- versus 4G-CAR-T cells in the presence of the indicated cytokines. Graphs
present the mean fold expansion ± SEM of T cells from n = 3 mice on days 5 and 9 after transduction. The experiment was repeated three times. (D) Expansion
of 2G-CAR-T cells in T cell medium supplemented with the indicated concentrations of hIL-15 (10, 20, 50, and 100 ng/ml) and 10 ng/ml hIL-7 in comparison to
4G-CAR-T cells expanded with 10 ng/ml hIL-7/IL-15. Cytokines were added from day 2 after transduction and replenished every 2–3 d. Shown are the mean
fold expansion values ± SEM of T cells from n = 5 mice. (E) Expansion of 4G-CAR-T cells cultured in the indicated concentrations of hIL-15 and 10 ng/ml hIL-7.
Shown are the mean values of fold expansion ± SEM of T cells from n = 5 mice. Experiments in D and E were repeated twice. (F) IL-2 production by 2G- versus
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We further showed that our methodologies enable the effi-
cient coexpression ofmIL-15 and a CAR (encoded by a bicistronic
vector) in murine T cells. Human CAR-T cells coexpressing hIL-
15 as a fusion protein tethered to the cell surface, or in a secreted
form, have previously demonstrated enhanced expansion and
persistence upon antigen stimulation (both in vitro and in vivo),
as well as increased tumor control (Hoyos et al., 2010; Markley
and Sadelain, 2010). As such, there are high expectations for
clinical efficacy of IL-15–CAR-T cells. In nonactivated murine
4G-CAR-T cells, we observed very low levels of mIL-15 in the
culture supernatant, but upon antigenic stimulation, signifi-
cantly higher amounts were detected, in line with reports for
hIL-15 CAR-T cells (Krenciute et al., 2017; Hoyos et al., 2010).
Elevated levels of pSTAT5 in the 4G- versus 2G-CAR-T cells in-
dicated active signaling by cytokine/receptor engagement. The
functional integrity of the coexpressed mIL-15 was further
supported by enhanced 4G-CAR-T cell proliferation and survival,
possibly due to up-regulation of the antiapoptoticmolecule Bcl-2 (Wu
et al., 2002; Shenoy et al., 2014). In addition, mIL-15 coexpression
promoted a TCM cell phenotype, limited PD-1 up-regulation,
and conferred superior effector function upon antigenic
challenge.
The culture methods presented herein comprising hIL-
7/hIL-15 in the medium permitted efficient murine CAR-T cell
expansion, which was significantly reinforced upon mIL-15
coexpression by CAR-T cells. This enabled us to further in-
vestigate the efficacy of 4G-CAR-T cells in vivo against B16
melanoma tumors. We observed higher tumor control and
persistence of 4G- as compared with the 2G-CAR-T cells and
sustained expression of the mIL-15 transgene. Moreover 4G-
CAR-T cells exhibited higher Bcl-2 levels, in line with our in-
vitro data, suggesting that mIL-15 can render CAR-T cells more
resistant to apoptosis in vivo. The coexpression of mIL-15 was
also associated with significantly lower up-regulation of PD-1,
an inhibitory receptor that can impair T cell function in the
TME (Ahmadzadeh et al., 2009).
Finally, evaluation of endogenous tumor immune infiltrate
revealed a significantly higher frequency of activated (CD69+
Ki67+) NK cells and fewer M2 (F4/80+ CD206+) macrophages
upon 4G- versus 2G-CAR-T cell transfer. As NK cells are asso-
ciated with delayed melanoma tumor growth (Nath et al., 2019),
and M2 macrophages have been shown to contribute to tumor
progression and metastasis (Poh and Ernst, 2018), the observed
TME remodeling upon 4G-CAR-T cell transfer is favorable for
tumor control. Our findings are consistent with prior studies.
For example, coadministration of IL-15 with tumor-directed
monoclonal antibodies enhanced Ab-dependent cellular cyto-
toxicity by augmenting both NK cell and macrophage activation
(Zhang et al., 2018). In another study, it was shown that the
absence of IL-15 in immunocompetent mice promotes the for-
mation of M2 macrophages (Gillgrass et al., 2014).
In summary, we have presented comprehensive and highly
reproducible methods for efficient retroviral transduction and
robust expansion of murine CAR-T cells endowed with favorable
properties for ACT studies in immunocompetent mice. We fur-
ther demonstrated that coexpression of mIL-15 directly promotes
CAR-T cell fitness and function and remodels the TME to favor
tumor control. As it is becoming apparent that endogenous im-
munity can play a critical role in either suppressing or supporting
CAR-T cell function in the TME (Kuhn et al., 2019), comprehensive
studies in immunocompetent mice are critical for accelerating the
translation of effective CAR therapies to the clinic.
Materials and methods
Cell culture
The murine brain endothelioma cell line bEnd3, the murine
immortalized heart endothelial cell line H5V, and the murine
leukemia cell line C1498 were cultured in DMEM-GlutaMAX
comprising 4,500 mg/liter glucose and 110 mg/liter sodium
pyruvate and supplemented with 10% heat-inactivated FBS
(Gibco, Thermo Fisher Scientific), 100 U/ml penicillin, and
100 µg/ml streptomycin sulfate. The melanoma cell line B16-F10
was grown as a monolayer in DMEM-GlutaMAX supple-
mented with 10% FBS, 100 U/ml of penicillin, and 100 µg/ml
streptomycin sulfate. Cells were passaged twice weekly to
maintain them under exponential growth conditions and were
routinely tested for mycoplasma contamination. The Phoenix
Eco retroviral ecotropic packaging cell line, derived from
immortalized normal human embryonic kidney cells, was
maintained in RPMI 1640-Glutamax medium supplemented
with 10% FBS, 100 U/ml penicillin, and 100 µg/ml strepto-
mycin sulfate. Primary murine T cells were cultured in RPMI
1640-Glutamax medium supplemented with 10% FBS, 100
U/ml penicillin, 100 µg/ml streptomycin sulfate, 1 mM sodium
pyruvate, 50 µM β-mercaptoethanol, and 10 mM nonessential
amino acids (referred to as murine T cell culture medium).
Murine T cell culture medium was further supplemented with
human cytokines as described in the method for T cell
expansion.
4G-CAR-T cells upon co-culture with target cells. Results present the mean concentration (pg/ml) ± SEM in triplicate wells with T cells pooled from n = 4 mice.
(G) Measurement of mIL-15 secretion by 2G- and 4G-CAR-T cells at 24 h after co-culture with target cells at a CAR+ T cell to target cell ratio of 2:1. Numbers
represent mean concentration (pg/ml) ± SEM in co-culture supernatants with T cells from n = 4 mice. (H) Expansion of 2G- versus 4G-CAR-T cells after co-
culture with target cells. Results present the mean number of CD8+ T cells ± SEM for n = 5 mice. (I) Shown are representative flow cytometric examples
indicating the numbers of CD8+ T cells in the co-cultures of 2G- and 4G-CAR-T cells with target cells on days 1 and 4 after co-culture. (J and K) Percentage (J) or
number (K) of dividing CD8+ T cells upon co-culture with bEnd3 cells. Results shown are mean values ± SEM of T cells from n = 4 mice. (L) Shown is a
representative flow cytometric analysis of CTV-stained CAR-T cells co-cultured with bEnd3 or H5V cells. (M) Quantification of target cell apoptosis on day 3
after co-culture with 2G- or 4G-CAR-T cells using Annexin V and 7-AAD staining. The graph presents mean values ± SEM of Annexin V+/7-AAD+ target cells
upon co-culture with T cells from n = 3 mice. (N) Representative dot plots of Annexin V+/7-AAD+ target cells following CAR-T cell co-culture. Experiments in
F–N were repeated three times. Statistical analyses were performed using a two-tailed unpaired Student’s t test (A and B) and a one-way ANOVA with Tukey
post hoc correction test (C–F, H, J, and K): *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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CAR construction
The retroviral vector pMSGV (murine stem cell virus [MSCV]–
based splice-gag vector) comprising the MSCV LTR was used as
the backbone for all CAR constructs. A 2G-CAR consisting of the
anti-VEGFR-2 scFv, DC101, the CD8α hinge (H), and TM region,
followed by the EDs of CD28 and CD3ζ (DC101-28-z), was kindly
provided by Dr. Steven A. Rosenberg (National Cancer Institute,
Bethesda, MD; Chinnasamy et al., 2010). The DC101-28-z CAR
was built by PCR amplification of a 362-bp fragment from the 2G
construct with the primers: 59-ACGCGCGGCCGCAACTACTAC
CAAGC-39 and 59-ACGCGTCGACGGGGCGGTACGCTGCAAAGT
CTC-39 followed by NotI and SalI digestion of both the PCR
Figure 7. 4G-CAR-T cells achieve higher in vivo tumor control and persistence than 2G-CAR-T cells. (A) Schematic of ACT study and ex vivo analysis.
(B) Assessment of tumor control over time for the different treatment groups. Results are expressed as mean tumor volume (mm3 ± SEM) with n = 18 mice per
group pooled from three independent experiments. The experiment was repeated four times. (C) Abundance of transferred T cells in the blood (day 11 after
transfer), as measured by CD45.1 staining (left) and CAR expression levels (right) (n = 6 mice per group). Shown are representative dot plots for the assessment
of CAR expression. The experiments in C (left and right) were repeated three and two times, respectively. (D) Number of transferred T cells (left) and relative
mRNA quantification of the CAR (middle) and mIL-15 (right) transgenes in the spleens (n = 5–6 mice per group). The experiment in the left panel was repeated
three times, and the experiments in the middle and right panels were repeated twice. (E) Abundance of transferred T cells in the tumors asmeasured by CD45.1
staining (n = 6–7 mice per group). Shown are representative dot plots for the frequency of tumor-residing CD45.1+ CD8+ T cells. The experiment was repeated
three times. (F) Relative mRNA quantification of the CAR (left) and mIL-15 (right) transgenes in the tumors (n = 5–6 mice per group). The experiments were
repeated twice. (G) Expression levels of Bcl-2 (MFI) in tumor-infiltrating transferred T cells (n = 6–8 mice per group) along with representative histograms. The
experiment was repeated three times. All experimental data show mean values ± SEM. Statistical analyses were performed using a two-way repeated
measures ANOVA with Tukey post hoc correction test (B) and a one-way ANOVA with Tukey post hoc correction test (C–G): *, P < 0.05; **, P < 0.01; ***, P <
0.001.
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product and the parental 2G vector, gel purification, and liga-
tion. To generate the 4G-CAR construct encoding both mIL-15
and the VEGFR-2–directed CAR (mIL-15-T2A-DC101-28-z), a
gene-string encoding the murine Igκ leader sequence followed
by codon-optimized mIL-15 and T2A, flanked by XhoI and EcoRI
restriction sites at the 59 and 39 ends, respectively, was syn-
thesized. The DC101-28-z construct and fragment were then
digested (XhoI and EcoRI), gel purified, and ligated together. All
genes strings were synthesized by GeneArt AG, and all con-
structs were fully sequenced by Microsynth AG.
Retrovirus production
High-titer, replication-defective retrovirus was produced and
concentrated as depicted in Fig. 1. Briefly, Phoenix Eco cells were
Figure 8. 4G-CAR-T cells coexpressingmIL-15
are characterized by lower PD-1 expression
than 2G-CAR-T cells in vivo and promote TME
remodeling. (A) Schematic of ACT study and
ex vivo analysis. (B–E) Assessment of Ki67 ex-
pression in the transferred T cells in the spleens
(B) and tumors (D) of all treatment groups. Rep-
resentative flow cytometry histograms showing
the frequency of Ki67 in the transferred T cells
in the spleens (C) and tumors (E). (F) Evaluation
of PD-1 expression on the transferred T cells in
the tumors. (G) Representative histograms
showing the frequency of PD-1 among the
transferred tumor-infiltrating T cells. (H) As-
sessment of the frequency of activated (CD69+
Ki67+) tumor-residing NK cells. (I) Representa-
tive contour plots showing the frequency of
activated tumor-residing NK cells. (J) Assess-
ment of the frequency of M2 (F4/80+ CD206+)
tumor-infiltrating macrophages among the CD45+
cells. (K) Representative contour plots showing
the frequency of tumor-residing M2 macro-
phages in all treatment groups. Graphs in B, D,
F, H, and J present mean frequencies ± SEM of
n = 10 mice pooled from two independent ex-
periments. Statistical analyses were performed
using a one-way ANOVA with Tukey post hoc
correction test (B, D, F, and H) and a one-way
ANOVA followed by Fisher’s least significant
difference test (J): *, P < 0.05; **, P < 0.01; ***,
P < 0.001; ****, P < 0.0001. FMO, fluorescence
minus one.
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seeded at 107 per T-150 tissue culture flask in 35 ml culture
medium (Fig. 1 A, 1) 24 h before transfection with 14.4 µg pCL-
Eco Retrovirus Packaging Vector and 21.4 µg pMSGV transfer
plasmid using Turbofect (Thermo Fisher Scientific; Fig. 1 A, 2).
All plasmids were purified using HiPure Plasmid Filter Max-
iprep Kit (Invitrogen, Thermo Fisher Scientific). For the trans-
fectionmixture, a 3:1 ratio of Turbofect/plasmid was prepared in
2 ml Opti-MEM and incubated for 30 min at room temperature
(RT; Fig. 1 A, 2). Medium was then removed from T-150 flasks
bearing 80–90% confluent Phoenix Eco cells and the transfection
mixture was applied and incubated for 1 min, followed by ad-
dition of 31 ml fresh medium (Fig. 1 A, 2). The viral supernatant
was discarded 20–24 h after transfection and replaced with
33ml freshmedium (Fig. 1 A, 3). At 48 (Fig. 1 A, 4) and 72 h (Fig. 1
A, 5) after transfection, the supernatant was harvested, and viral
particles were concentrated by ultracentrifugation for 2 h at
24,000 g at 4°C with a Beckman JS-24 rotor (Beckman Coulter)
and resuspended in 0.4mlmurine T cell medium. The retrovirus
was then used immediately, or aliquoted, frozen on dry ice, and
stored at −80°C.
Determination of viral titer
Titers were determined in a small-scale, single-round trans-
duction (described below) of 105 activated murine T cells added
to 96 non-treated well plates (Corning Falcon) already loaded
with threefold serial dilutions (up to 1 in 2,187) of concentrated
retrovirus, in a final volume of 50 μl. After 7 d of expansion,
CAR expression was evaluated by specific staining and flow
cytometric analysis (described below). Titers (expressed as
transducing units/milliliter) were calculated according to the
formula: (F/100) × N × 20 × D, where F is the percentage of
CAR+ T cells, N is the number of T cells at the time of trans-
duction (usually 105 cells), and D is the fold dilution of virus
used in transduction.
Murine T cell and leukemia cell transduction
As depicted in Fig. 1 B, murine T cells were isolated from single-
cell suspensions of dissociated spleens from CD45.1+ congenic
C57BL/6 mice bred in-house at the animal facility of the Uni-
versity of Lausanne (UNIL; Epalinges, Switzerland) using the
EasySepMouse T Cell Isolation Kit (StemCell Technologies; Fig. 1
B, 1.1). T cells were plated at 106/ml in 24- or 48-well plates in
T cell medium (described above) and stimulated with αCD3/
CD28 Ab-coated beads (Invitrogen) at a bead to cell ratio of 2:1 and
50 IU/ml hIL-2 (Glaxo; Fig. 1 B, 1.1). Non–treated cell-culture
grade 48- or 24-well plates (Corning Falcon) were precoated
with 0.25 ml or 0.5 ml, respectively, of recombinant Retro-
Nectin (Takara Bio) at a final concentration of 20 μg/ml,
overnight (O/N) at 4°C (Fig. 1 B, 1.2). 1 d after T cell activation,
the retronectin-precoated plates were washed with PBS, blocked
with 2% BSA in PBS for 30min at RT (Fig. 1 B, 2.1). Subsequently,
plates were washed once, retrovirus was added at the MOI in-
dicated in the figures, and plates were then spun at 2,000 g for
1.5 h at 32°C (Fig. 1 B, 2.2). The supernatants were then aspirated,
and 0.5 to 106 of 24 h activated T cells were transferred to each
coated well (48- or 24-well plates; Fig. 1 B, 2.3). The plates were
centrifuged for 10 min at 300 g and incubated O/N (Fig. 1 B, 2.3).
In some experiments the transduction procedure was performed
at 48 h, or at both 24 and 48 h after activation. The cultures were
maintained at a cell density of 0.5 to 106 cells/ml and replenished
with fresh T cell medium (supplemented with hIL-2 alone or hIL-
2 followed by hIL-7/IL-15 on day 2 after transduction) every
other day (Fig. 1 B, 3). At day 7, CAR surface expression was
assessed by flow cytometric analysis (as described below), and
the rested engineered T cells were adjusted for equal expression
before functional in vitro and in vivo assays (Fig. 1 B, 4).
Murine C1498 leukemia cells were transduced as described
above for primary murine T cells, except that they were not
activated and were maintained afterwards in DMEM-GlutaMAX
complete medium at a cell density of 3 × 105 viable cells/ml.
T cell activation, expansion, viability, and
phenotype assessment
Murine T cells were activated for 24 h with (i) αCD3/CD28 Ab-
coated beads (Gibco, Thermo Fisher Scientific) at a bead to cell
ratio of 2:1 and 50 IU/ml of hIL-2 (Glaxo), (ii) plate-coated αCD3
Ab (5 µg/ml; eBioscience) plus soluble αCD28 Ab (2 µg/ml;
eBioscience) and hIL-2 (50 IU/ml), or (iii) Concanavalin A (2 µg/
ml; Sigma), hIL-7 (1 ng/ml; Miltenyi) and 50 IU/ml hIL-2 before
transduction. Transduced T cells were cultured at a concentra-
tion of 0.5–106 cells/ml in T cell medium enriched with 50 IU/ml
hIL-2 only or with 10 ng/ml of both hIL-7 and hIL-15 (Miltenyi)
from day 2 after transduction onwards. T cells were typically
counted every 2–3 d. T cell expansion was calculated by dividing
the absolute number of expanded T cells at each time point
during culture by the respective number on day 0 (T cell
transduction). T cell viability was assessed by trypan blue
staining, and the phenotype was assessed by cell-surface stain-
ing of CD44 and CD62L followed by flow cytometric analysis.
Cytokine release assays
Cytokine release assays were performed in triplicate in 96-well
plates by co-culturing 0.5 × 105 transduced T cells with 0.5 × 105
target cells per well in 200 µl T cell medium. In some experi-
ments, CD8+ T cells were first sorted from transduced T cells
using the EasySep Mouse CD8+ T Cell Isolation Kit (StemCell
Technologies) before co-culturing them with target cells. After
20–24 h of co-culture, the supernatants were assayed for the
presence of IFN-γ and granzyme B by commercial ELISA Kits
(BioLegend and eBioscience, respectively). IL-2 was measured
by Cytokine Bead Array as described by the manufacturer (BD
Biosciences).
Measurement of mIL-15
For intracellular mIL-15 protein quantification, transduced
T cells were washed and placed O/N in cytokine-free medium at
a concentration of 106 T cells/ml. The next day, the T cells were
harvested, lysed via one freeze/thaw cycle, and pelleted by
centrifugation, and mIL-15 was measured in the supernatant by
ELISA (Murine IL-15 Standard ABTS ELISA Development Kit;
Peprotech) according to the manufacturer’s instructions. mIL-15
was similarly quantified by ELISA in the supernatants of Phoe-
nix Eco cells at 72 h after transfection and the supernatants of
transduced C1498 cells at 24 h after incubation of equal numbers
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of transduced cells in 48-well plates. For the measurement of
mIL-15 in the supernatants of T cell cultures stimulated with
recombinant protein, plate wells were coated with soluble
mVEGFR-2 protein (1 µg/ml in PBS) or control BSA protein (2%
in PBS) for 4 h at RT and washed with PBS, followed by addition
of equal numbers of transduced T cells in the coated wells. mIL-
15wasmeasured in the supernatants by ELISA at 24 h after T cell
activation. For T cell cultures stimulated with endothelial cells,
mIL-15was evaluated in the supernatants 24 h after co-culture at
a CAR+ T cell to target ratio of 2:1.
T cell proliferation assay
Endothelial target cells were plated at a density of 104 per well in
triplicate in 96-well flat-bottom plates in 200 µl total volume.
The next day, T cells were labeled with 5 µM CellTrace Violet
(CTV; Molecular Probes, Life Technologies) in PBS with 1% FBS at
37°C for 20 min. The reaction was then quenched with complete
medium, and the cells washed and then co-cultured with the indi-
cated established endothelial cell monolayers at a CAR+ T cell to
target ratio of 2:1 for 4 d. Subsequently, total cells were harvested
by Accutase treatment (Thermo Fischer Scientific), washed, and
stained with indicated labeled Abs. Cell division was evaluated by
dilution of the dye in live CD8+ T cells and flow cytometric analysis.
CAR-T cell cytotoxicity
Established endothelial monolayers (15,000 cells/well of a 96-
well plate) were co-cultured with CAR-T cells and control T cells
at an effector to target ratio of 3:1 for 3 d. The cells were sub-
sequently collected by Accutase treatment, washed, and stained
for Annexin V and 7-aminoactinomycin D (7-AAD) using an
Apoptosis Detection Kit (BD Pharmingen) according to the
manufacturer’s instructions.
Flow cytometry: Surface and intracellular staining
For flow cytometric analysis, cells were surface stained using
antibodies against CD3ε (145-2C11), CD4 (GK1.5, RM4-5), CD8α
(53–6.7), CD25 (PC61), CD44 (IM7), CD45.1 (A20), CD45 (30F/11),
CD62L (MEL-14), CD69 (H1-2F3), IL-15-Rα (6B4C88), PD-1 (29F.1A12),
Ly-6G (1A8), CD11b (M1/70), CD11c (N418), F4/80 (BM8), CD206
(C068C2), NK-1.1 (PK136), CD19 (6D5), and MHC class II (M5/
114.15.2). Abs were purchased from eBioscience and BioLegend
or produced in-house from hybridomas by the flow cytometry
platform. DC101-CAR expression by retrovirally transduced
T cells was detected by incubation with soluble mouse VEGFR-
2–hIgG-Fc fusion protein (R&D Systems) followed by staining
with labeled goat anti-hIgG Fc (clone HP6017; Biolegend).
Thy1.1-T cells were stained in parallel as a negative control.
VEGFR-2 expression by mouse endothelial cell lines was eval-
uated by cell-surface staining with rat anti-VEGFR-2 Ab (clone
Avas12; BioLegend) and matched isotype control (Rat IgG2a κ
isotype; clone RTK2758; BioLegend). For detection of phos-
phorylated STAT5, cells were fixed with BD Cytofix Fixation
Buffer at 4°C for 15 min and permeabilized with BD Phosflow
Perm Buffer III for 30 min at 4°C. Intracellular phospho-
staining was performed for 1 h at RT in the dark with Ab
against phospho-STAT5 (Tyr694; D47E7 XP Rabbit mAb 4322;
Cell Signaling). For intracellular staining of mIL-15 (clone
AIO.3; eBioscience), Bcl-2 (clone 10C4; eBioscience), and Ki67
(clone SolA15; eBioscience), T cells were fixed and then per-
meabilized using the FoxP3 transcription factor staining buffer
set (eBioscience) according to the manufacturer’s recom-
mendations. For the detection of mIL-15, the cells were further
washed and incubated for 30 min with anti-rat IgG2a. To dis-
criminate dead cells, 7-AAD (BioLegend) staining was per-
formed. Live/dead fixable Aqua Dead cell staining was used to
exclude dead cells in the ex vivo analysis of immune cells de-
rived from the spleens, tumors, and tumor-draining lymph
nodes according to the manufacturer’s instructions (Molecular
Probes, Life Technologies). Data were acquired with a BD flow
cytometer and analyzed using FlowJo software (Tree Star).
Mouse strains
Female C57BL/6 mice aged 6–8 wk were purchased from Envigo
and housed at the animal facility at the UNIL in compliance with
guidelines. All in vivo experiments were conducted in accordance
and with approval from the Service of Consumer and Veterinary
Affairs of the Canton of Vaud. CD45.1+ congenic on a C57BL/6
background were bred and housed in the UNIL animal facility.
Adoptive CAR-T cell transfer in tumor-bearing mice
B16 tumor cells were harvested with 0.05% trypsin, washed, and
resuspended in PBS for injection. 105 tumor cells were injected
subcutaneously in the flank of C57BL/6 mice, aged 8–12 wk. 8 d
later (average tumor volume, 20–40 mm3), the mice received
5 Gy of sublethal total body irradiation and grouped (n ≥ 5 mice/
group) for comparative average tumor volumes. On days 9 and
11, mice were treated with intravenous transfer of 8–9 × 106
CD45.1+ 4G- or 2G-CAR-T cells or control Thy1.1-T cells. Mice
were carefully monitored, and tumor length (L; greatest longi-
tudinal measurement) and width (W; greatest transverse mea-
surement) measured by caliper every 2–3 d. Tumor volumes (V)
were calculated using the formula: V = (L × W2)/2. The mean
tumor volumes for each group are plotted ± SEM. Mice were
sacrificed once tumors reached 1,000 mm3 or, according to
regulation, if they became distressed or moribund.
Evaluation of in vivo persistence of adoptively transferred
T cells
Blood, spleens, tumors and tumor-draining lymph nodes were
harvested from differently treated mice. Blood was treated with
a RBC lysing buffer (BD Pharm Lyse, BD Biosciences), and
spleens or tumor-draining lymph nodes were gently crushed
through a 40-µm cell strainer followed by RBC lysis. Tumor
fragments were cut into pieces with scissors and then digested
in RPMI supplemented with 200 µg/ml Liberase TL (Roche) and
5 U/ml DNase I (Sigma-Aldrich) for 1 h at 37°C on a rocker,
followed by passage through a 40-µm cell strainer. To calculate
the absolute number of viable CD8+ CD45.1+ T cells in the spleen
cell preparations, the splenic cell count was multiplied with the
frequency of CD8+ CD45.1+ T cells among total live cells.
Quantitative PCR
Cells extracted from dissociated tumors were lysed using TRIzol
reagent (Invitrogen, Thermo Fisher Scientific). Total RNA was
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isolated using the RNeasy Mini Kit (Qiagen). After treatment
with RNase-free DNase I (Qiagen), 400 ng of total RNA was
reverse transcribed using PrimeScript First Strand cDNA Syn-
thesis Kit (Takara Bio), as indicated by the manufacturer.
Quantitative real-time PCR was performed according to the
commercial protocol using SYBR Green Fast PCR Master Mix
(Thermo Fisher Scientific) and the 7500 Fast Real-Time PCR
System (Applied Biosystems). Primers to specifically amplify
regions of the DC101 scFv of the CAR cassette, or the mIL-15
transgene, were designed using the GenScript website and are
as follows: DC101 forward, 59-GCAACCCAAACTCCTCATCT-39;
DC101 reverse, 59-TATCATCAGCCTCCACAGGA-39; IL-15 for-
ward, 59-CCAGGATCTACAGGCGACAA-39; IL-15 reverse, 59-ATG
CTCTGGATCAGGCTCTC-39.
PCR amplification of the housekeeping gene GAPDH was
performed as a control, and to allow normalization of samples.
The following primers were used for GAPDH: GAPDH forward,
59-AGGTCGGTGTGAACGGATTTG-39; GAPDH reverse, 59-TGT
AGACCATGTAGTTGAGGTCA-39. Each sample was run in trip-
licate, and each experiment included three nontemplate control
wells. The relative mRNA levels (fold change) of each transgene
among the different samples were quantified using the com-
parative 2−ΔΔCt method.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 8
software. Analysis of differences between two groups was per-
formed using an unpaired two-tailed Student’s t test. Statistical
analyses of three or more groups were performed using a one-
way ANOVA followed by the post hoc test stated in the figure
legends. Statistical analysis of tumor growth curves was per-
formed using a two-way repeated-measures ANOVAwith Tukey
post hoc correction test. Significance levels are indicated in the
figures (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
Online supplemental material
Fig. S1 shows the impact of different activation methods on the
expression of Ki67 and CAR by transduced T cells. Fig. S2 shows
the comparison of effector functions between hIL-7/IL-15– and
hIL-2–expanded CD8+ CAR-T cells. Fig. S3 shows the absence of
IL-15-Rα expression on murine C1498 leukemia cells, the ex-
pression of Bcl-2 by 4G- and 2G-CAR-T cells, and the impact of
increasing concentrations of hIL-15 in the medium on the ex-
pansion of 2G- and 4G-CAR-T cells. Fig. S4 shows the flow cy-
tometry gating strategy for the ex vivo analysis of the different
immune cell populations. Fig. S5 shows the frequency of Ki67
expression in 2G- and 4G-CAR-T cells as well as control Thy1.1
T cells in the tumor-draining lymph nodes extracted from all the
treatment groups.
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Supplemental material
Figure S1. Stimulation with αCD3/CD28 beads leads to the highest T cell activation and CAR transduction efficiency. (A) Representative histograms of
Ki67 expression in differently activated T cells. (B) Graph bars present the mean percentage CAR expression ± SEM on differently activated and transduced
CD8+ and CD4+ T cells on day 7 after transduction. All results show mean ± SEM of T cells from n = 5 mice (B, left) or n = 3 mice (B, right). The experiment was
repeated twice. Statistical analyses were performed using a one-way ANOVA with Tukey post hoc correction test: **, P < 0.01. FMO, fluorescence minus one.
Figure S2. Enhanced effector functions of CD8+ CAR-T cells expanded with hIL-7/IL-15 versus hIL-2. Secretion levels of IFN-γ, granzyme B, and IL-2 by
CD8+ CAR-T cells expanded in hIL-2 versus hIL-7/IL-15, upon co-culture with bEnd3 or H5V cells. Graph bars present the mean cytokine concentration (pg/ml) ±
SEM of triplicate wells with T cells pooled from n = 5 mice. The experiment was repeated twice. Statistical analyses were performed using a one-way ANOVA
with Tukey post hoc correction test: *, P < 0.05; ****, P < 0.0001.
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Figure S3. Enhanced properties of 4G-CAR-T cells efficiently coexpressing mIL-15. (A) Assessment of IL-15-Rα expression on murine C1498 leukemia
cells. Representative flow cytometry histogram of IL-15-Rα expression on C1498 cells. (B) Graph bars present the mean MFI of Bcl-2 ± SEM in 2G- versus 4G-
CAR-T cells on days 2 and 5 after transduction from n = 3 mice. (C) Representative histograms showing intracellular levels of Bcl-2 in CD8+ 2G- versus 4G-CAR-
T cells. The experiments in A–Cwere repeated three times. (D) Fold expansion of 2G- and 4G-CAR-T cells (by day 9 after transduction) cultured in the indicated
concentrations of hIL-15 (10, 20, 50, and 100 ng/ml) and 10 ng/ml hIL-7 relative to 4G-CAR-T cells expanded in medium supplemented with 10 ng/ml hIL-7/IL-
15. Shown are the mean values of relative fold expansion ± SEM of T cells from n = 5 mice. The experiment was repeated twice. Statistical analyses were
performed using a two-tailed unpaired Student’s t test (B) and a one-way ANOVA with Tukey post hoc correction test (D): **, P < 0.01; ***, P < 0.001; ****, P <
0.0001. FMO, fluorescence minus one.
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Figure S4. Workflow demonstrating the ex vivo gating strategy. Shown is the flow cytometry gating strategy for evaluating the phenotype of adoptively
transferred CD45.1+ CD8+ T cells (A1–A3), the activation status of NK cells (B1) and the identification of M2 macrophages (C1), DCs (D), and B cells (E). FSC-A,
forward scatter area; FSC-H, forward scatter height.
Lanitis et al. Journal of Experimental Medicine S3
Murine 4G-CAR-T cells co-engineered to express IL-15 https://doi.org/10.1084/jem.20192203
Figure S5. Ex vivo analysis of CAR-T cell–treated mice. (A and B) Assessment of Ki67 expression in the transferred T cells in the tumor-draining lymph
nodes and representative flow cytometry histograms. (C–F) Assessment of the frequency of B cells (CD19+ MHCII+) among CD45+ cells in the tumors (C) and
spleens (E) of treated mice along with representative contour plots shown in D and F, respectively. (G and H) Assessment of the frequency of tumor-residing
DCs (CD11b− CD11c+) among CD45+ cells of treated mice (G) and representative contour plots (H). Graphs in A, C, E, and G present mean frequencies ± SEM
obtained at day 6 after ACT from n = 10 mice pooled from two independent experiments. Statistical analysis in A was performed using a one-way ANOVA with
Tukey post hoc correction test: **, P < 0.01.
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